In:
Chemotherapy, S. Karger AG, Vol. 51, No. 2-3 ( 2005), p. 120-125
Kurzfassung:
〈 i 〉 Background: 〈 /i 〉 To evaluate the efficacy and safety of combination chemotherapy of cisplatin (5-day continuous infusion) and docetaxel for the treatment of previously untreated patients with advanced non-small-cell lung cancer (NSCLC). 〈 i 〉 Materials and Methods: 〈 /i 〉 Eligible patients had an ECOG performance status of 0–2 with measurable NSCLC. Patients received continuous infusion cisplatin 20 mg/m 〈 sup 〉 2 〈 /sup 〉 /day on 5 days and bolus docetaxel 60 mg/m 〈 sup 〉 2 〈 /sup 〉 /day (day 1; PiD therapy) at a 4-week interval. 〈 i 〉 Results: 〈 /i 〉 Forty-three patients were enrolled. The mean number of cycles administered per patient was 2, and ranged from 1 to 4. The response rate was 49% (95% confidence interval, 33.9–63.8%). The median survival time was 47 weeks and the 1-year survival rate was 47%. The major toxic effects were grade 3 or 4, neutropenia (88%), leukopenia (81%), thrombocytopenia (14%) and anemia (42%). There were no treatment-related deaths. 〈 i 〉 Conclusion: 〈 /i 〉 PiD therapy was a well-tolerated and active regimen for patients with advanced NSCLC. The major toxicity was neutropenia.
Materialart:
Online-Ressource
ISSN:
0009-3157
,
1421-9794
Sprache:
Englisch
Verlag:
S. Karger AG
Publikationsdatum:
2005
ZDB Id:
1482111-4
SSG:
15,3
